Pharming Group NV
NASDAQ:PHAR

Watchlist Manager
Pharming Group NV Logo
Pharming Group NV
NASDAQ:PHAR
Watchlist
Price: 16.61 USD 0.12% Market Closed
Market Cap: 1.1B USD

Intrinsic Value

The intrinsic value of one PHAR stock under the Base Case scenario is 18.12 USD. Compared to the current market price of 16.61 USD, Pharming Group NV is Undervalued by 8%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PHAR Intrinsic Value
18.12 USD
Undervaluation 8%
Intrinsic Value
Price
Base Case Scenario

Valuation History
Pharming Group NV

What is Valuation History?
Ask AI Assistant
What other research platforms think about PHAR?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is PHAR valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Pharming Group NV.

Explain Valuation
Compare PHAR to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about PHARM?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Pharming Group NV

Current Assets 278m
Cash & Short-Term Investments 166.2m
Receivables 44m
Other Current Assets 67.8m
Non-Current Assets 196m
Long-Term Investments 6.7m
PP&E 25m
Intangibles 135m
Other Non-Current Assets 29.3m
Current Liabilities 88m
Accounts Payable 78.2m
Other Current Liabilities 9.8m
Non-Current Liabilities 121m
Long-Term Debt 121m
Efficiency

Free Cash Flow Analysis
Pharming Group NV

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Pharming Group NV

Revenue
362.3m USD
Cost of Revenue
-36.6m USD
Gross Profit
325.7m USD
Operating Expenses
-288.9m USD
Operating Income
36.8m USD
Other Expenses
-36.7m USD
Net Income
100k USD
Fundamental Scores

PHAR Profitability Score
Profitability Due Diligence

Pharming Group NV's profitability score is 38/100. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin
Strong 3Y Average Gross Margin
Healthy Operating Margin
Declining Gross Margin
38/100
Profitability
Score

Pharming Group NV's profitability score is 38/100. The higher the profitability score, the more profitable the company is.

PHAR Solvency Score
Solvency Due Diligence

Pharming Group NV's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Negative Net Debt
59/100
Solvency
Score

Pharming Group NV's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PHAR Price Targets Summary
Pharming Group NV

Wall Street analysts forecast PHAR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PHAR is 18.35 USD with a low forecast of 17.5 USD and a high forecast of 19.48 USD.

Lowest
Price Target
17.5 USD
5% Upside
Average
Price Target
18.35 USD
10% Upside
Highest
Price Target
19.48 USD
17% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Pharming Group NV
does not pay dividends
Shareholder Yield

Current shareholder yield for PHARM is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one PHAR stock?

The intrinsic value of one PHAR stock under the Base Case scenario is 18.12 USD.

Is PHAR stock undervalued or overvalued?

Compared to the current market price of 16.61 USD, Pharming Group NV is Undervalued by 8%.

Back to Top